Yanqin Bian

Dr. Yanqin Bian


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FCFeifei Cai
Feifei Cai
YBYanqin Bian
Yanqin Bian
RWRong Wu
Rong Wu
YSYang Sun
Yang Sun
XCXiao-Le Chen
Xiao-Le Chen
SSShi-Bing Su
Shi-Bing Su
Yinchenhao decoction (YCHD) is a classical Traditional Chinese Medicine (TCM) formula that has been widely used in the treatment of liver fibrosis caused by chronic hepatitis B and jaundice for more than 1800 years. The purpose of this study was to investigate the apoptosis regulation mechanisms of YCHD and its active components suppresses liver fibrosis. The active components and putative targets of YCHD were predicted by network pharmacology approach. Functional and pathway enrichment analysis were presented in the present study by using clusterProfiler. Further, experimental validation was done by using terminal deoxynucleotidyl transferase (TDT) dUTP nick end labelling (TUNEL) assay and western blotting in dimethylnitrosamine (DMN)-induced liver fibrosis rats, and cell proliferation assay, apoptosis assay, and western blotting in human hepatic L02 cells and LX2 cells. 45 active compounds in YCHD formula, 592 potential target proteins and 1191 liver fibrosis-related human genes were identified. Functional and pathway enrichment analysis indicated that YCHD obviously influenced TNF, PI3K-Akt signaling pathways. Further, In vivo experiment indicated that YCHD treatment not only attenuated the symptoms of liver fibrosis, but also decrease the apoptosis of hepatic parenchyma cells. Moreover, in vitro experiments showed that rhein, kaempferol and quercetin treatments remarkably decreased the protein levels of cleaved caspase-3 and increased p-ERK1/2, PI3K and Bcl-XL protein expression in TNF-α-stimulated L02 cells. On the contrary, rhein, kaempferol, aloe-emodin and quercetin inhibited the proliferation of LX2 cells and up-regulated the protein levels of Bax and cleaved caspase-8. In conclusion, 45 active components and 296 potential targets of YCHD against liver fibrosis were identified by the analysis of network pharmacology and transcriptomics combination. The mechanisms of YCHD against liver fibrosis were involved in the regulation of multiple targets, especially affecting the apoptosis-related signaling pathways.

Verified
Journal Article
Open access
PDF file
DFDanping Fan
Danping Fan
XHXiaojuan He
Xiaojuan He
YBYanqin Bian
Yanqin Bian
QGQingqing Guo
Qingqing Guo
KZKang Zheng
Kang Zheng
ALAiping Lu
Aiping Lu
Triptolide (TP), an active component isolated from Tripterygiumwilfordii Hook F, has therapeutic potential against rheumatoid arthritis (RA). However, the underlying molecular mechanism has not been fully elucidated. The aim of this study is to investigate the mechanisms of TP acting on RA by combining bioinformatics analysis with experiment validation. The human protein targets of TP and the human genes of RA were found in the PubChem database and NCBI, respectively. These two dataset were then imported into Ingenuity Pathway Analysis (IPA) software online, and then the molecular network of TP on RA could be set up and analyzed. After that, both in vitro and in vivo experiments were done to further verify the prediction. The results indicated that the main canonical signal pathways of TP protein targets networks were mainly centered on cytokine and cellular immune signaling, and triggering receptors expressed on myeloid cells (TREM)-1 signaling was searched to be the top one shared signaling pathway and involved in the cytokine and cellular immune signaling. Further in vitro experiments indicated that TP not only remarkably lowered the levels of TREM-1 and DNAX-associated protein (DAP)12, but also significantly suppressed the activation of janus activating kinase (JAK)2 and signal transducers and activators of transcription (STAT)3. The expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in lipopolysaccharides (LPS)-stimulated U937 cells also decreased after treatment with TP. Furthermore, TREM-1 knockdown was able to interfere with the inhibition effects of TP on these cytokines production. In vivo experiments showed that TP not only significantly inhibited the TREM-1 mRNA and DAP12 mRNA expression, and activation of JAK2 and STAT3 in ankle of rats with collagen-induced arthritis (CIA), but also remarkably decreased production of TNF-α, IL-1β and IL-6 in serum and joint. These findings demonstrated that TP could modulate the TREM1 signal pathway to inhibit the inflammatory response in RA.

28 June 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CWChao Wu
Chao Wu
YBYanqin Bian
Yanqin Bian
BLBingjie Lu
Bingjie Lu
DWDan Wang
Dan Wang
NANisma Lena Bahaji Azami
Nisma Lena Bahaji Azami
MSMingyu Sun
Mingyu Sun
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and has become a huge public health issue worldwide. Inhibition of nucleotide oligomerization domain-like receptors containing pyrin domain 3 (NLRP3) inflammasome is a potential therapeutic strategy for NAFLD. Currently, there are no drugs targeting NLRP3 inflammasome for clinical treatment of NAFLD. In this study, we explored the efficacy and mechanism of rhubarb free anthraquinones (RFAs) in treating NAFLD by inhibiting NLRP3 inflammasome. Methods: First, NLRP3 inflammasome was established in mouse bone marrow-derived macrophages (BMDMs), Kuffer cells and primary hepatocytes stimulated by lipopolysaccharide (LPS) and inflammasome inducers to evaluate the effect of RFAs on inhibiting NLRP3 inflammasome and explore the possible mechanism. Further, Mice NAFLD were established by methionine and choline deficiency diet (MCD) to verify the effect of RFAs on ameliorating NAFLD by inhibiting NLRP3 inflammasome. Results: Our results demonstrated that RFAs including rhein/diacerein, emodin, aloe emodin and 1,8-dihydroxyanthraquinone inhibited interleukin-1 beta (IL-1β) but had no effect on tumor necrosis factor-alpha (TNF-α). Similar results were also showed in mouse primary hepatocytes and Kuffer cells. RFAs inhibited cleavage of caspase-1, formation of apoptosis-associated speck-like protein containing a CARD (ASC) speck, and the combination between NLRP3 and ASC. Moreover, RFAs improved liver function, serum inflammation, histopathological inflammation score and liver fibrosis. Conclusions: RFAs including rhein/diacerein, emodin, aloe emodin and 1,8-dihydroxyanthraquinone ameliorated NAFLD by inhibiting NLRP3 inflammasome. RFAs might be a potential therapeutic agent for NAFLD. Graphical

3 April 2012 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JDJin-Xing Du
Jin-Xing Du
MSMingyu Sun
Mingyu Sun
GDGuang-Li Du
Guang-Li Du
FLFeng-Hua Li
Feng-Hua Li
YMYongping Mu
Yongping Mu
PLPing Liu
Ping Liu
Huangqi decoction was first described in Prescriptions of the Bureau of Taiping People's Welfare Pharmacy in Song Dynasty (AD 1078), and it is an effective recipe that is usually used to treat consumptive disease, anorexia, and chronic liver diseases. Transforming growth factor beta 1 (TGFβ1) plays a key role in the progression of liver fibrosis, and Huangqi decoction and its ingredients (IHQD) markedly ameliorated hepatic fibrotic lesions induced by ligation of the common bile duct (BDL). However, the mechanism of IHQD on hepatic fibrotic lesions is not yet clear. The purpose of the present study is to elucidate the roles of TGFβ1 activation, Smad-signaling pathway, and extracellular signal-regulated kinase (ERK) in the pathogenesis of biliary fibrosis progression and the antifibrotic mechanism of IHQD.

23 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LZLin Zheng
Lin Zheng
XAXinyu A
Xinyu A
SMShiyu Ma
Shiyu Ma
BXBo Xu
Bo Xu
ZXZheng Xiang
Zheng Xiang
LXLianbo Xiao
Lianbo Xiao
The accumulation of lactate in synovial microenvironment of rheumatoid arthritis (RA) patients is closely correlated with disease activity, with elevated lactate levels serving as both biomarkers and pathogenic mediators in RA progression. In recent years, mounting evidence has demonstrated that lactate-driven metabolic reprogramming constitutes the central hub of the immune-metabolic-bone destruction axis in RA. The accumulation of lactate in the synovial microenvironment triggers a cascade of immunoregulatory effects, and these metabolic alterations create a self-perpetuating cycle of inflammation and tissue destruction, which represents the fundamental cause of RA chronicity. Therefore, lactate metabolism has been identified as a therapeutic target, opening new avenues for precision medicine approaches in RA treatment. Novel therapeutic strategies targeting lactate dehydrogenase A (LDHA) inhibitors, monocarboxylate transporters (MCTs), and enzymes that regulate lactylation have shown promising preclinical results. Furthermore, combination therapies pairing metabolic modulators with conventional biologics demonstrate synergistic effects in suppressing inflammatory pathways while improving drug penetration into synovial tissues. Additionally, patient stratification based on lactate metabolic profiles enables personalized treatment approaches. In summary, targeting lactate metabolism represents a paradigm shift in RA treatment from symptom management toward metabolic restoration. The integration of metabolic modulators with existing therapeutic regimens holds promise for achieving sustained remission and preventing long-term joint damage.

5 January 2025 in Heliyon
Verified
Journal Article
Open access
YLYang Liu
Yang Liu
YSYi Shen
Yi Shen
HDHongbai Ding
Hongbai Ding
DHDongyi He
Dongyi He
PCPeng Cheng
Peng Cheng
QZQi Zhu
Qi Zhu
Ankylosing spondylitis (AS) is a chronic autoimmune disease characterized by systemic inflammation, often resulting in fusion of the spine and peripheral joints. This study aimed to investigate the role of innate lymphoid cells (ILCs) in AS patients with high disease activity. Blood samples were collected from healthy controls and AS patients categorized by high or low disease activity. Systemic inflammation was quantified through C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR), alongside disease activity scores such as Ankylosing Spondylitis Disease Activity Score(ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index(BASDAI). The levels of different ILC subsets and the expression of T-box transcription factor 21 (T-bet) and retinoic-acid-receptor-related orphan receptor gamma (RORγt) in peripheral blood were analyzed via flow cytometry. Additionally, 24 cytokines in plasma were measured using a Luminex liquid suspension chip. The proportion of total ILCs and the distribution of ILC subsets in peripheral blood varied with AS disease activity scores. Specifically, the frequencies of total ILCs and ILC3s were significantly elevated in AS patients with high disease activity (AS-HA). The frequency and absolute number of ILC3s showed a positively correlation with disease severity scores. Furthermore, T-bet+ILC3s were significantly increased in the AS-HA group. Plasma levels of IL-17A and IFN-γ were positively correlated with the frequency of circulating-ILC3 in AS patients. These findings highlight the critical role of T-bet+ILC3s in the inflammatory process of AS, suggesting their potential as a therapeutic target for managing AS disease.